Nuvilex Has Massive Credibility Issues and They Can’t Be Ignored
Their credibility gap is as wide as the Grand Canyon and people may yet wonder why this stock is stuck in the mud. And why they have zero large institutional investors.
Financial: Any legit biotech with Nuvilex’s financials would be a disaster considered in dire-straights. Nuvilex’s auditors themselves included such ‘going-concern’ warnings in the company10-K, but yet Nuvilex doesn’t address this at all to shareholders. They did though release multiple misleading PR’s related to two non-financing financing deals which were a joke. Lincoln Capital, Chardan Capital? What of them? Not much. Nuvilex has an amount of money the equivalent of what is inside a child’s piggy bank.
Management: I’ve posted this all before but the Red Flags here are so entirely numerous, how could alarm bells not ring for large experienced investors or firms when they do their research? Management’s past activities in OTC traded companies is atrocious. China Tel/VelaTel, Trussnet, efoodsafety, Plandai Bio, Freedom Environmental, Westmoore Capital, The Isaac Capital Group, the Topaz Group. All with strong past connections to NVLX management, all have followed similar patterns of returning nothing to shareholders, with zero lasting accomplishments. The CEO’s connection to Westmoore Capital alone should be enough to frighten most people. Any experienced investor or large firm can research this info in minutes.
And this is also ignoring management’s complete lack of experience in actually running a biotech.
Scientific: Again, saying nothing new here, but everything Nuvilex holds is dated. The crux of everything they dangle to retail investors is from the mid to late 90s. Patents filed from 96-98. Trials in 1999, 2002. Austrianova bankruptcy in 2008. What money was ever made? You can’t afford to live in a bubble. There have been thousands of biotechs over the last 15 years working on various cancer treatments. Billions of dollars spent. Some have worked, most have failed. But time and money are going to be the ultimate truth here. And time and money have shown that the patents under the Nuvilex license are not worth squat to the greater industry. New attempts have treatment have emerged, new endpoints and expectations.
Bavarian Nordic gave up on this in 2004. Oxford Pharmaceuticals had a similar program from around 2005-2008, but they abandoned it as well. But both have moved on to new ways to treat cancer.
Nuvilex is kicking a rusty tin can, for the sake of stock.
